Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
J Surg Case Rep ; 2022(3): rjac068, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35280056

ABSTRACT

Coronavirus disease 2019 (COVID-19) was thought to have respiratory symptoms as the main manifestation, but it has become clear that extrapulmonary symptoms such as gastrointestinal disorders also occur. There are several reports of intussusception associated with COVID-19 in children, but these are rare in adults. In this report, we present a case of cystic intestinal duplication that enlarged during the course of COVID-19 treatment and resulted in intussusception. Right hemicolectomy was performed for intussusception due to the cystic lesion. To the best of our knowledge, this is the first resected case of intussusception due to alimentary tract duplication after COVID-19 infection.

2.
Clin J Gastroenterol ; 12(1): 15-19, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30206777

ABSTRACT

Immune checkpoint inhibitors may have different clinical effects compared with conventional anticancer drugs. An 85-year-old male received chemotherapy for recurrent gastric cancer. As liver metastasis progressed, nivolumab was introduced as a fourth line treatment. Progression of liver metastasis in size was observed in CT after 3 courses of nivolumab therapy. Nivolumab treatment was discontinued, because the general condition of the patient also worsened. However, his general condition improved as hepatobiliary enzyme levels, inflammatory response, and tumor markers improved. Liver metastasis was shrinking on the image, so we resumed nivolumab therapy. To the authors' knowledge, this is the first case of pseudoprogression undergoing immunotherapy for gastric cancer. In this case, the antitumor effect was exhibited in a delayed manner and the tumor shrinkage was obtained.


Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/secondary , Antineoplastic Agents, Immunological/therapeutic use , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Neoplasm Recurrence, Local/drug therapy , Nivolumab/therapeutic use , Stomach Neoplasms/drug therapy , Adenocarcinoma/diagnostic imaging , Aged, 80 and over , Disease Progression , Humans , Liver Neoplasms/diagnostic imaging , Male , Neoplasm Recurrence, Local/pathology , Stomach Neoplasms/pathology , Time Factors , Tomography, X-Ray Computed , Treatment Outcome
3.
Gan To Kagaku Ryoho ; 44(10): 867-869, 2017 Oct.
Article in English | MEDLINE | ID: mdl-29066681

ABSTRACT

A 32-year-old woman was found to have a gastric adenocarcinoma with multiple bone metastases. Chemotherapy in the first, second and third-line was not effective. Blood examinations showed disseminated intravascular coagulation(DIC)at the end of the second-line chemotherapy. The fourth-line chemotherapy, infusional 5-fluorouracil and levofolinate calcium was performed. This resulted in a good response for DIC. This palliative therapy was effective and safety.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Disseminated Intravascular Coagulation/etiology , Stomach Neoplasms/drug therapy , Adenocarcinoma/complications , Adenocarcinoma/surgery , Adult , Female , Fluorouracil/administration & dosage , Gastrectomy , Humans , Levoleucovorin/administration & dosage , Stomach Neoplasms/complications , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery , Treatment Outcome
4.
Gan To Kagaku Ryoho ; 41(10): 1227-30, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25335704

ABSTRACT

PURPOSE: To evaluate the safety and efficacy of a modified administration schedule of docetaxel, cisplatin, and fluorouracil (mDCF)in patients with advanced gastric cancer with gastrointestinal stenosis in clinical practice. METHODS: In the chemotherapy-naïve patients who had metastatic or recurrent histologically confirmed gastric cancer, docetaxel(40mg/m2), levofolinate(200mg/m / / / 2), fluorouracil(400mg/m2)on day 1, fluorouracil 1,000 mg/m2d-2 days intravenous continuous in fusion beginning on day 1, and cisplatin(40mg/m2)on day 3 was administered every 2 weeks. RESULTS: Six patients received mDCF therapy. In 5 patients with measurable disease, the overall response rate was 86%. Median progression-free survival was 310 days and median overall survival was 599 days. Symptom improvement after the first cycle of mDCF was obtained in all patients. Grade 3 or 4 leukopenia and neutropenia were observed in 2(33%)and 6(100%)patients, respectively. There were no treatment-related deaths. CONCLUSION: mDCF seems to be active against metastatic and recurrent gastric cancer with gastrointestinal stenosis. Further study is needed to confirm the efficacy and safety of mDCF regimen.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Gastric Outlet Obstruction/etiology , Intestinal Obstruction/etiology , Stomach Neoplasms/drug therapy , Stomach Neoplasms/pathology , Aged , Cisplatin/administration & dosage , Docetaxel , Female , Fluorouracil/administration & dosage , Gastrointestinal Diseases , Humans , Male , Middle Aged , Recurrence , Stomach Neoplasms/complications , Taxoids/administration & dosage
6.
Cancer Sci ; 101(9): 2011-8, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20626753

ABSTRACT

To study the mechanisms of the highly liver-metastatic character of colon carcinoma cells, we studied the expression pattern of surface integrins on LS-LM6 (a highly liver-metastatic human colon cancer cell line) and the effects of hepatocyte-derived soluble factors on cell migration. LS-LM6 showed significantly higher expression of integrin αvß5, a ligand for vitronectin (VN), as compared with its parental cell line (LS174T). A conditioned medium of cultured mouse hepatocytes enhanced VN-mediated cell migration of LS-LM6, which was blocked by neutralizing antibody against integrin αvß5, while the medium did not affect cell adhesion to VN-coated plastic surfaces. The conditioned medium induced phosphorylation of erbB3 and its heterodimeric partner, erbB2. Heregulin (HRG), a ligand for erbB3, exerted similar effects on VN-mediated cell migration and phosphorylation of erbB3 and erbB2. The conditioned medium contained HRG, and depletion of HRG from the medium by pre-absorption with HRG antibody abolished its effects on cell migration. Heregulin (HRG) was expressed in some hepatocytes in the liver with carcinoma cell metastasis. Furthermore, knockdown of integrin αv and erbB3 by small-interfering RNAs significantly inhibited cell migration induced by HRG as well as liver metastasis in vivo. Finally, we found that HRG-induced cell migration was associated with marked phosphorylation of Akt and that cell migration was suppressed by treatment with specific inhibitors of phosphatidylinositol 3-kinase. Our study suggests that hepatocyte-derived HRG might participate in a highly liver-metastatic phenotype of LS-LM6 through enhancement of integrin αvß5-mediated cell migration and erbB3/erbB2 signaling.


Subject(s)
Colonic Neoplasms/metabolism , Hepatocytes/metabolism , Integrin alpha5beta1/metabolism , Liver Neoplasms/metabolism , Neuregulin-1/metabolism , Receptor, ErbB-3/metabolism , Animals , Blotting, Western , Cell Adhesion/drug effects , Cell Line, Tumor , Cell Movement/drug effects , Cells, Cultured , Colonic Neoplasms/genetics , Colonic Neoplasms/pathology , Culture Media, Conditioned/metabolism , Culture Media, Conditioned/pharmacology , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry , Integrin alpha5beta1/genetics , Liver Neoplasms/genetics , Liver Neoplasms/secondary , Male , Mice , Mice, SCID , Neoplasms, Experimental/genetics , Neoplasms, Experimental/metabolism , Neoplasms, Experimental/pathology , Neuregulin-1/pharmacology , Phosphorylation/drug effects , RNA Interference , Receptor, ErbB-2/genetics , Receptor, ErbB-2/metabolism , Receptor, ErbB-3/genetics , Reverse Transcriptase Polymerase Chain Reaction , Transplantation, Heterologous
7.
Hepatogastroenterology ; 54(75): 775-9, 2007.
Article in English | MEDLINE | ID: mdl-17591060

ABSTRACT

BACKGROUND/AIMS: Obturator hernia presenting in elderly women accompanies a high rate of bowel resection because of strangulation. Open laparotomy is usually indicated in general anesthesia. However, minimal invasive approaches would be advantageous unless resection is necessary. We aimed to determine clinical and radiological criteria for the selection of these patients. METHODOLOGY: Preoperative clinical data from 23 cases and known signs of ischemia on CT examination were retrospectively compared to operative findings. RESULTS: Identification of patients having necrotic bowel was not possible by any clinical parameter or their combination. Patients with necrosis had longer history of symptoms, but acute onset less than 24 h does not exclude the need of resection (negative predictive value 83%). Impaired contrast enhancement was frequently seen on CTs independently from the onset of symptoms suggesting early vascular compromise (sensitivity 80%, specificity 22%), but not helping the differentiation. Signs of ischemia (bowel wall thickening and/or ascites) were present in every resected case while both were absent in 69% of patients having viable bowel. CONCLUSIONS: Absence of ischemic signs on nonenhanced CT may allow safe and more accurate selection of patients for minimal invasive surgery than any clinical or anamnestic parameter in obturator hernia.


Subject(s)
Hernia, Obturator/diagnostic imaging , Intestinal Obstruction/diagnostic imaging , Intestine, Small/blood supply , Intestine, Small/diagnostic imaging , Ischemia/diagnostic imaging , Aged , Aged, 80 and over , Female , Hernia, Obturator/complications , Hernia, Obturator/surgery , Humans , Intestinal Obstruction/etiology , Intestinal Obstruction/surgery , Intestine, Small/surgery , Ischemia/etiology , Ischemia/surgery , Preoperative Care , Retrospective Studies , Survival Analysis , Tomography, X-Ray Computed
8.
J Med Ultrason (2001) ; 33(2): 115, 2006 Jun.
Article in English | MEDLINE | ID: mdl-27277731

ABSTRACT

There is a marked paucity of reports on contrast-enhanced ultrasonography (US) for focal splenic disease in the literature, and there are no previously reported contrast-enhanced US findings for splenic granuloma. We report the case of a 77-year-old cirrhotic woman with isolated splenic granulomas. We detail the diagnostic difficulty encountered in this case and briefly review the literature.

9.
J Med Ultrason (2001) ; 33(3): 173-6, 2006 Sep.
Article in English | MEDLINE | ID: mdl-27277855

ABSTRACT

We present a rare case of isolated liver metastasis from renal cell carcinoma 12 years after complete resection of the primary site. Such abnormal behavior of renal cell carcinoma has been reported elsewhere in the literature; thus, careful long-term surveillance should be performed in patients with a past history of renal cell carcinoma, even after radical resection of the primary site. We present also contrast-enhanced sonographic findings for this case.

10.
J Med Ultrason (2001) ; 33(3): 177-80, 2006 Sep.
Article in English | MEDLINE | ID: mdl-27277856

ABSTRACT

Splenic inflammatory pseudotumor is a rare pathology, and the literature stresses the difficulty of preoperative diagnosis. There are no previous reports of contrast-enhanced ultrasound findings for this tumor in the literature. Our case appears to be the first to be examined using this technique. In our case, contrast-enhanced ultrasound showed the mass to be homogeneously and less enhanced than the surrounding parenchyma in all phases, and it included fine enhanced spots. We also briefly review the literature.

11.
Gan To Kagaku Ryoho ; 32(8): 1179-81, 2005 Aug.
Article in Japanese | MEDLINE | ID: mdl-16121925

ABSTRACT

A 62-year-old man reported to our hospital with serious complaints of abdominal pain, vomiting, and weight loss. An endoscopic examination detected a type 2 tumor of the descending limb of the duodenum. With a diagnosis of adenocarcinoma based on the biopsy finding, the patient was subjected to surgery. Laparotomy revealed the presence of a duodenal tumor disseminating to the omentum at the site where the transverse colon is attached. Pancreatoduodenectomy and partial resection of the transverse colon were carried out. CT conducted 6 months after surgery did not show any signs of tumor recurrence; but one year later, extensive tumor dissemination was noted on the hepatic surface. Upon consultation with the patient, a regimen of 80 mg/day of TS-1 given for 4 weeks followed by 2 weeks of a drug-free period was initiated. Six months later, the growth of tumor became arrested, improving his QOL. Nine months later, the tumor growth was progressive and the patient died two years after operation. The patient could gain long-term survival after operation. The TS-1 regimen applied in the present case may constitute a therapeutic strategy to be considered for similar conditions in future.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Duodenal Neoplasms/drug therapy , Neoplasm Seeding , Omentum/pathology , Oxonic Acid/therapeutic use , Pyridines/therapeutic use , Tegafur/therapeutic use , Antimetabolites, Antineoplastic/administration & dosage , Colectomy , Drug Combinations , Duodenal Neoplasms/pathology , Duodenal Neoplasms/surgery , Humans , Liver/pathology , Male , Middle Aged , Oxonic Acid/administration & dosage , Pancreaticoduodenectomy , Pyridines/administration & dosage , Tegafur/administration & dosage
12.
Gan To Kagaku Ryoho ; 32(1): 77-9, 2005 Jan.
Article in Japanese | MEDLINE | ID: mdl-15675587

ABSTRACT

We reported a case of effective weekly paclitaxel administration for gastric cancer recurrence with carcinomatous pericarditis. A 69-year-old man underwent distal gastrectomy for gastric cancer in December 2001. However, he was re-admitted to the hospital for dyspnea in November 2002. A diagnosis of cardiac tamponade caused by gastric cancer relapse was made, and the patient was treated by weekly paclitaxel administration (90 mg/body) after drainage. It was effective in preventing reaccumulation of the pericardial effusion until his death 73 days after the diagnosis. It is thought that weekly paclitaxel administration can be a treatment for carcinomatous pericarditis.


Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Neoplasm Recurrence, Local/complications , Paclitaxel/therapeutic use , Pericarditis/drug therapy , Stomach Neoplasms/complications , Aged , Drainage , Drug Administration Schedule , Gastrectomy , Humans , Male , Pericardial Effusion/prevention & control , Pericarditis/etiology , Stomach Neoplasms/surgery
13.
Ther Apher Dial ; 8(3): 185-9, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15154868

ABSTRACT

For the treatment of multiple organ failure (MOF) through sepsis, we have commonly applied various blood purification modalities during the perioperative period. From January 1996 to December 2000, 33 patients with MOF through sepsis were admitted and operated on in the First Department of Surgery, Akita University School of Medicine, and 21 of these 33 patients were treated using various blood purification modalities during the perioperative period: endotoxin-adsorbing therapy using polymyxin B (PMX) in 17 patients, continuous hemofiltration (CHF)/continuous hemodiafiltration (CHDF) in 15 patients, and plasma exchange (PE) and CHDF in 3 patients. Of the outcome of these 33 patients with MOF through sepsis, 17 survived and 16 died (48% mortality). Of the 21 patients with MOF through sepsis treated by surgery and blood purification, 12 survived and 9 died (43% mortality). We evaluated APACHE II and the number of failed organs before operation. Amongst the group with 12 survivors and 9 deaths, Acute Physiology and Chronic Health Evaluation II (APACHE II) was 15 +/- 5, 23 +/- 2 and the number of failed organs was 2.7 +/- 0.7, 3.9 +/- 0.8, respectively. An increased APACHE II score and number of failed organs were significantly associated with mortality. As to the treatment of MOF through sepsis due to acute peritonitis, patients with APACHE II scores ranging from 15 to 20, and those with 2-3 failed organs seem to be the candidates for the application of blood purification during the perioperative period.


Subject(s)
Multiple Organ Failure/therapy , Sepsis/therapy , APACHE , Aged , Anti-Bacterial Agents/therapeutic use , Female , Hemodiafiltration/adverse effects , Hemodiafiltration/standards , Hemofiltration/adverse effects , Hemofiltration/standards , Humans , Japan , Male , Middle Aged , Multiple Organ Failure/complications , Peritonitis/etiology , Plasma Exchange/adverse effects , Plasma Exchange/standards , Polymyxins/therapeutic use , Sepsis/complications , Survival Analysis , Thromboembolism/etiology , Treatment Outcome
14.
Dig Surg ; 21(1): 48-53, 2004.
Article in English | MEDLINE | ID: mdl-14707393

ABSTRACT

BACKGROUND/AIM: To preserve pancreatic function, segmental pancreatectomy has been proposed for benign or low-malignancy tumors in the pancreatic body. Indications for the procedure, however, are still controversial. METHODS: In this study, we investigated the advantages and disadvantages of segmental pancreatectomy compared with distal pancreatectomy and subsequently determined indications for segmental pancreatectomy. RESULTS: The distal pancreatectomy patients had shorter operation times, lower incidence of operative complications, and shorter hospital stays compared to segmental pancreatectomy patients. Endocrine function in distal pancreatectomy patients deteriorated compared to that of segmental pancreatectomy patients. The postoperative 75-gram oral glucose tolerance test showed a diabetic pattern in 3 of 7 distal pancreatectomy patients, whereas none of the segmental pancreatectomy patients became diabetic after surgery. The relation between the length of the removed pancreas and plasma glucose at 2 h after the 75-gram glucose intake showed a significant correlation. CONCLUSION: According to our results, if the length of removed pancreas is longer than 12 cm, the patients will have a risk of acquiring diabetes. In those cases, the segmental pancreatectomy should be considered.


Subject(s)
Pancreatectomy/methods , Pancreatic Neoplasms/surgery , 4-Aminobenzoic Acid/urine , Aged , Blood Glucose/analysis , Body Weight , Diabetes Mellitus/etiology , Female , Humans , Length of Stay , Male , Middle Aged , Pancreatectomy/adverse effects , Retrospective Studies
15.
Surg Today ; 32(2): 183-5, 2002.
Article in English | MEDLINE | ID: mdl-11998952

ABSTRACT

We herein describe a case of acute emphysematous cholecystitis in which the patient presented with symptoms of ileus. The patient was a 72-year-old man with no history of diabetes mellitus. He presented with epigastric pain, vomiting, and low-grade fever. Plain abdominal radiography showed some intestinal gas and niveau, and he was admitted to our hospital with a diagnosis of ileus. The next day, the abdominal pain increased and was accompanied by muscular defense. Plain radiography and computed tomography of the abdomen were carried out, and an emergency laparotomy was performed under a diagnosis of panperitonitis due to a perforation of the gallbladder caused by acute emphysematous cholecystitis. The patient made favorable progress after the operation and was discharged on postoperative day 14. Percutaneous transhepatic gallbladder drainage has been increasingly performed for the treatment of acute emphysematous cholecystitis. but when a perforation of the gallbladder is suspected, a laparotomy first should be considered.


Subject(s)
Cholecystitis/complications , Emphysema/complications , Intestinal Obstruction/etiology , Acute Disease , Aged , Cholecystitis/diagnosis , Emphysema/diagnosis , Humans , Intestinal Obstruction/diagnosis , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...